ACS Journal Cancer shared a post on X about a recent paper by Jacob Sands et al. published in Cancer Journal:
“In the phase 2 DeLLphi-301 trial, tarlatamab showed durable responses in SCLC, but adverse events management is critical.
How to manage? Read more.”
Jacob Sands, Medical Oncologist at Dana-Farber Cancer Institute, shared this post, adding:
“Excited to get this guidance out for management of pateints on tarlatamab. CRS and ICANS manageable.
Check out guidance on dysguesia which is surprisingly effective. Appreciate all co-authors who provided valuable insights for this manuscript. It’s improved my management too!”
Authors: Jacob Sands, Stéphane Champiat, Horst-Dieter Hummel, Sujoy Mukherjee, Taofeek Owonikoko et al.
More posts featuring ACS Journal Cancer and Jacob Sands.